Indonesia Secures Commitment for 40 Million Doses of Self-Funded Vaccines

Consumer Services & Health

Lite

Yosepha Pusparisa 30/04/2021 15:00 WIB

URL has been copied

Memuat...

Indonesia has secured commitments for 40 million doses of Covid-19 vaccines for the "gotong royong" (community-based) or independent vaccination program. These vaccines are from three brands: Sinopha

A Font Kecil
A Font Sedang
A Font Besar

Access single data

Indonesia Secures Commitment for 40 Million Doses of Self-Funded Vaccines

Want to get more access to Data Stories with a more affordable price? Subscribe.

By subscribing, you join us in presenting quality data.

Get:

Premium Data Stories access
Comfortable reading without ads
Download data in XLS, PDF, and image format
Access to data source information

Basic

~~Rp100.000~~

Rp50.000/month

Professional

~~Rp100.000~~

Rp150.000/month

Institutional For organizations

We accept the following payments:

Some payment methods are still in the process of being activated.

Community-Driven Vaccine Supply

Download

Source

A Small Font
A Medium Font
A Bigger Font

Indonesia has secured a commitment of 40 million doses of Covid-19 vaccines for the "gotong royong" (community-based) vaccination program, also known as the independent vaccination program. Based on data from PT Biofarma (Persero), these Covid-19 vaccine commitments come from three brands: Sinopharm (China), Sputnik V (Russia), and CanSino (China).

Sinopharm will supply 15 million doses of the Covid-19 vaccine. Deliveries will begin at the end of April 2021 and continue until the fourth quarter of 2021.

For the Sputnik V brand of Covid-19 vaccine, the supply is estimated to reach 20 million doses. In the initial phase, five million doses of the Sputnik V vaccine will be delivered from April to July 2021.

Meanwhile, five million doses of the CanSino brand vaccine will be delivered to Indonesia. The details are as follows: three million doses will be delivered from July to September 2021, and the remaining two million doses in the fourth quarter of 2021.

Editor : Dimas Jarot Bayu

"Disclosure: This is an AI-generated translation of the original article. We strive for accuracy, but please note that automated translations may contain errors or slight inconsistencies."